Ilumetri

Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

100 mg SC at wk 0 & 4, & every 12 wk thereafter.

Hypersensitivity. Clinically important active infection eg, active TB.

Immediately discontinue administration if serious hypersensitivity reaction occurs. Alternate inj sites. Do not inj into areas where skin is affected by plaque psoriasis or is tender, bruised, red, hard, thick, or scaly. Potential to increase risk of infection. Caution in patients w/ chronic infection or history of recurrent or recent serious infection. Closely monitor if patient develops serious infection & do not administer tildrakizumab until infection resolves. Evaluate for TB infection prior to treatment initiation. Closely monitor for signs & symptoms of active TB during & after treatment. Consider anti-TB therapy prior to initiating tildrakizumab treatment in patients w/ past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Complete all appropriate immunisations prior to treatment initiation. Wait at least 4 wk after receiving live viral or bacterial vaccination before starting tildrakizumab. Patients on tildrakizumab should not receive live vaccines during treatment & for at least 17 wk after treatment. No studies in patients w/ renal or hepatic impairment. Women of childbearing potential should use effective contraception during treatment & for at least 17 wk after treatment. Avoid use during pregnancy. Discontinue breastfeeding or discontinue/abstain from therapy. Safety & efficacy in childn & adolescents <18 yr have not yet been established.

URTI, headache, diarrhoea, gastroenteritis, back pain, nausea, inj site pain.

Do not concurrently give w/ live vaccines. Safety & efficacy have not been evaluated in combination w/ other immunosuppressive agents, including biologics, or phototherapy.

Immunosuppressants

L04AC17 - tildrakizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

P₁S₁S₃